Scientific Advisors


Sunil Sharma, MD

  • Deputy Director, Clinical Sciences, TGen, an affiliate of City of Hope
  • Presidential Professor of Cancer Research, Director of Oncology
  • Novartis: Head of G/I program and phase 1 unit
  • Memorial Sloan Kettering: Head of phase 1 programs


Brian J. Druker, MD

  • Director, Oregon Health & Science University, Knight Cancer Institute
  • Developer of Gleevec
  • Oncology Fellow, Harvard Medical School
  • Lasker Award - 2009


Kapil Bhalla, MD

  • Professor, Department of Leukemia, Division of Cancer Medicine
  • The University of Texas MD Anderson Cancer Center

Andrew Spencer, MD

  • Head of Service, Malignant Haematology & Stem Cell Transplantation, Alfred Health- So. Australia Health Consortium
  • Professor of Hematology, Myeloma Research Group, Australian Centre for Blood Diseases, Central Clinical School, Faculty of Medicine, Nursing & Health Sciences, Monash University

       Alexander Lazar          

  • Director, Selective Pathology Fellowhip training Program, MD Anderson
  • Professor, Department of Pathology University of Texas MD Anderson
  • Professor of Translational Molecular Pathology. 

© 2017 Betacat Pharmaceuticals Inc.